HDL and Diabetes.

Cochran, BJ; Manandhar, B; Rye, K-A

HDL and Diabetes.

Cochran, BJ Manandhar, B

Rye, K-A

Permalink

Publisher:: Springer Nature Singapore
Publication Type:: Journal Article
Citation:: Adv Exp Med Biol, 2022, 1377, pp. 119-127
Issue Date:: 2022

Closed Access

	Filename	Description	Size
	978-981-19-1592-5_9.pdf	Published version	188.05 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Cochran, BJ
dc.contributor.author	Manandhar, B https://orcid.org/0000-0003-1276-6954
dc.contributor.author	Rye, K-A
dc.date.accessioned	2023-02-26T21:54:23Z
dc.date.available	2023-02-26T21:54:23Z
dc.date.issued	2022
dc.identifier.citation	Adv Exp Med Biol, 2022, 1377, pp. 119-127
dc.identifier.isbn	9789811915918
dc.identifier.issn	0065-2598
dc.identifier.issn	2214-8019
dc.identifier.uri	http://hdl.handle.net/10453/166438
dc.description.abstract	Diabetes is a worldwide public health issue, with the number of cases expected to reach 642 million by 2040. Patients with diabetes are at a two- to four-fold increased risk of developing cardiovascular disease. This chapter focuses on the anti-diabetic and cardioprotective functions of plasma high-density lipoproteins (HDLs). HDLs and the main HDL apolipoprotein, apoA-I, improves pancreatic beta cell function. ApoA-I also improves insulin sensitivity. The development of novel, bifunctional HDL-based interventions are a promising therapeutic option for the treatment of cardiometabolic diseases.
dc.format	Print
dc.language	eng
dc.publisher	Springer Nature Singapore
dc.relation.ispartof	Adv Exp Med Biol
dc.relation.isbasedon	10.1007/978-981-19-1592-5_9
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences
dc.subject.classification	General & Internal Medicine
dc.subject.mesh	Apolipoprotein A-I
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Diabetes Mellitus, Type 2
dc.subject.mesh	Humans
dc.subject.mesh	Insulin-Secreting Cells
dc.subject.mesh	Lipoproteins, HDL
dc.subject.mesh	Humans
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Diabetes Mellitus, Type 2
dc.subject.mesh	Lipoproteins, HDL
dc.subject.mesh	Apolipoprotein A-I
dc.subject.mesh	Insulin-Secreting Cells
dc.title	HDL and Diabetes.
dc.type	Journal Article
utslib.citation.volume	1377
utslib.location.activity	United States
utslib.for	11 Medical and Health Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-26T21:54:21Z
pubs.publication-status	Published
pubs.volume	1377

Abstract:

Diabetes is a worldwide public health issue, with the number of cases expected to reach 642 million by 2040. Patients with diabetes are at a two- to four-fold increased risk of developing cardiovascular disease. This chapter focuses on the anti-diabetic and cardioprotective functions of plasma high-density lipoproteins (HDLs). HDLs and the main HDL apolipoprotein, apoA-I, improves pancreatic beta cell function. ApoA-I also improves insulin sensitivity. The development of novel, bifunctional HDL-based interventions are a promising therapeutic option for the treatment of cardiometabolic diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166438